Keever Taylor and colleagues reported that rapamycin-treated Treg cultures from MS patients had enhanced suppressor functions and contained high levels of CD4+Foxp3+ cells compared with healthy controls, suggesting that blockade of mTOR1 promotes Treg development and function (71). This evidence concerns the gene FOXP3 and myeloid sarcoma.